PortfoliosLab logo
ARQT vs. PANW
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARQT and PANW is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

ARQT vs. PANW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and Palo Alto Networks, Inc. (PANW). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%400.00%December2025FebruaryMarchAprilMay
-38.00%
381.80%
ARQT
PANW

Key characteristics

Sharpe Ratio

ARQT:

0.95

PANW:

0.68

Sortino Ratio

ARQT:

1.78

PANW:

1.20

Omega Ratio

ARQT:

1.20

PANW:

1.15

Calmar Ratio

ARQT:

0.87

PANW:

0.95

Martin Ratio

ARQT:

5.30

PANW:

2.88

Ulcer Index

ARQT:

13.20%

PANW:

8.84%

Daily Std Dev

ARQT:

73.21%

PANW:

36.25%

Max Drawdown

ARQT:

-95.02%

PANW:

-47.98%

Current Drawdown

ARQT:

-63.45%

PANW:

-9.48%

Fundamentals

Market Cap

ARQT:

$1.82B

PANW:

$124.56B

EPS

ARQT:

-$1.16

PANW:

$1.76

PS Ratio

ARQT:

9.35

PANW:

14.53

PB Ratio

ARQT:

11.66

PANW:

19.49

Total Revenue (TTM)

ARQT:

$146.97M

PANW:

$6.59B

Gross Profit (TTM)

ARQT:

$131.10M

PANW:

$4.86B

EBITDA (TTM)

ARQT:

-$82.41M

PANW:

$1.26B

Returns By Period

In the year-to-date period, ARQT achieves a -2.98% return, which is significantly lower than PANW's 3.61% return.


ARQT

YTD

-2.98%

1M

1.69%

6M

29.95%

1Y

69.15%

5Y*

-11.25%

10Y*

N/A

PANW

YTD

3.61%

1M

23.60%

6M

-2.57%

1Y

24.44%

5Y*

39.67%

10Y*

22.30%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ARQT vs. PANW — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT
The Risk-Adjusted Performance Rank of ARQT is 8282
Overall Rank
The Sharpe Ratio Rank of ARQT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ARQT is 8383
Sortino Ratio Rank
The Omega Ratio Rank of ARQT is 7676
Omega Ratio Rank
The Calmar Ratio Rank of ARQT is 8282
Calmar Ratio Rank
The Martin Ratio Rank of ARQT is 8888
Martin Ratio Rank

PANW
The Risk-Adjusted Performance Rank of PANW is 7575
Overall Rank
The Sharpe Ratio Rank of PANW is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of PANW is 7171
Sortino Ratio Rank
The Omega Ratio Rank of PANW is 6868
Omega Ratio Rank
The Calmar Ratio Rank of PANW is 8383
Calmar Ratio Rank
The Martin Ratio Rank of PANW is 7979
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARQT vs. PANW - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Palo Alto Networks, Inc. (PANW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ARQT Sharpe Ratio is 0.95, which is higher than the PANW Sharpe Ratio of 0.68. The chart below compares the historical Sharpe Ratios of ARQT and PANW, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00December2025FebruaryMarchAprilMay
0.95
0.68
ARQT
PANW

Dividends

ARQT vs. PANW - Dividend Comparison

Neither ARQT nor PANW has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ARQT vs. PANW - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, which is greater than PANW's maximum drawdown of -47.98%. Use the drawdown chart below to compare losses from any high point for ARQT and PANW. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-63.45%
-9.48%
ARQT
PANW

Volatility

ARQT vs. PANW - Volatility Comparison

Arcutis Biotherapeutics, Inc. (ARQT) has a higher volatility of 19.14% compared to Palo Alto Networks, Inc. (PANW) at 15.37%. This indicates that ARQT's price experiences larger fluctuations and is considered to be riskier than PANW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%December2025FebruaryMarchAprilMay
19.14%
15.37%
ARQT
PANW

Financials

ARQT vs. PANW - Financials Comparison

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Palo Alto Networks, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
71.36M
2.26B
(ARQT) Total Revenue
(PANW) Total Revenue
Values in USD except per share items

ARQT vs. PANW - Profitability Comparison

The chart below illustrates the profitability comparison between Arcutis Biotherapeutics, Inc. and Palo Alto Networks, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
90.3%
73.5%
(ARQT) Gross Margin
(PANW) Gross Margin
ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a gross profit of 64.46M and revenue of 71.36M. Therefore, the gross margin over that period was 90.3%.

PANW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Palo Alto Networks, Inc. reported a gross profit of 1.66B and revenue of 2.26B. Therefore, the gross margin over that period was 73.5%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported an operating income of -7.63M and revenue of 71.36M, resulting in an operating margin of -10.7%.

PANW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Palo Alto Networks, Inc. reported an operating income of 240.40M and revenue of 2.26B, resulting in an operating margin of 10.7%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a net income of -10.79M and revenue of 71.36M, resulting in a net margin of -15.1%.

PANW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Palo Alto Networks, Inc. reported a net income of 267.30M and revenue of 2.26B, resulting in a net margin of 11.8%.